But in its letter last November, the FDA questioned the methodology of some of those studies. The 1995 death of a woman receiving this therapy appears to have prompted the FDA's concern, though her death has not been linked to terbutaline use.
None is without complications.
We want to continue to prescribe judiciously, the way we always have. Lam, a district chairman of the American College of Obstetricians and Gynecologists, is also concerned health plans will be frightened away. But Sidelines, which provides support to women with high-risk pregnancies, says patients have notified it of at least five HMOs that have either stopped or restricted coverage, and five more are considering doing so.